Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Neratinib and Trastuzumab with or without oral Vinorelbine in HER2-positive metastatic breast cancer
2022-002582-15Phase 2Terminated
- Sponsor
- Medical University of Graz
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of neratinib, trastuzumab and vinorelbine in HER2-enriched breast cancer (HER2+) (2 arms), sponsored by Medical University of Graz. Primary endpoint: Progression-free survival at 6 months. Started Mar 2023; status: terminated.
02
Drugs
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on 2022-002582-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002582-15.